Replimune Group, Inc. Common Stock (REPL) Stock
Key stats
- Market cap
- $2.06B
- Price / Earnings ratio
- -8.1x
- EPS (TTM)
- -$2.79
- Volume
- Loading
- 52-week high
- $23.41
- 52-week low
- $1.50
Source: third-party data provider, as of November 13, 2026
Compare with REPL
Recent news

Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
REPL

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
REPL

Replimune: 3 Key Takeaways for Long-Term Investors
Replimune: 3 Key Takeaways for Long-Term Investors
REPL

REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky
REPL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 72.20
- MACD 12/26/9
- 2.53
- EMA 9 of MACD
- 1.81
- MACD histogram
- 0.73
- SMA 50
- $14.51
- Price above SMA 50
- EMA 50
- $15.31
- Price above EMA 50
- SMA 200
- $9.86
- Price above SMA 200
- EMA 200
- $10.98
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
No data available
Source: third-party data provider
Latest news

Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
REPL

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?
REPL

Replimune: 3 Key Takeaways for Long-Term Investors
Replimune: 3 Key Takeaways for Long-Term Investors
REPL

REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky
REPL

Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc.
Robbins LLP Urges REPL Stockholders to Contact the Firm for Information About the Class Action Against Replimune Group, Inc.
REPL

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
REPL

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - REPL
REPL

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
REPL

Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
REPL

REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
REPL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Replimune Group, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Sushil Patel Ph.D. | CEO & Director | 1971 |
| Mr. Philip Astley-Sparke F.S.A. | Executive Chairman | 1971 |
| Ms. Emily Luisa Hill | Chief Financial Officer | 1980 |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer | 1966 |
| Ms. Carolyn Trott | Senior Vice President of Quality Assurance | — |
| Ms. Kari Jeschke | Senior Vice President of Regulatory Affairs | — |
| Ms. Michelle DiNapoli | Chief Commercial Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 72.20
- MACD 12/26/9
- 2.53
- EMA 9 of MACD
- 1.81
- MACD histogram
- 0.73
- SMA 50
- $14.51
- Price above SMA 50
- EMA 50
- $15.31
- Price above EMA 50
- SMA 200
- $9.86
- Price above SMA 200
- EMA 200
- $10.98
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $21.00
- Average
- $26.00
- High
- $31.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.8 | -3.2 | ||||||||||
| 2022 | -32.3 | -17.2 | +6.3 | -8.2 | -13.6 | +19.9 | +4.9 | +1.5 | -9.9 | +7.2 | +7.4 | +36.1 |
| 2023 | +5.7 | -23.4 | -20.8 | -4.8 | +8.5 | +25.6 | -3.9 | -0.6 | -13.2 | -7.7 | -21.8 | -28.0 |
| 2024 | -10.5 | +9.2 | -8.9 | -17.9 | -18.7 | +65.4 | +6.8 | -0.5 | +6.6 | -1.2 | +18.3 | -10.6 |
| 2025 | +11.3 | -7.5 | -19.6 | +16.4 | -6.8 | -2.9 | -23.2 | -28.9 | -29.0 | +131.1 | +7.4 | +0.1 |
| 2026 | -21.0 | +9.6 | +6.8 | -66.2 | +247.6 | +23.0 | -0.2 | +28.5 | -15.5 | +30.9 | +11.7 |



